Latest Articles

Publication Date
Promega wins FDA approval as companion diagnostic for Keytruda-Lenvima combo in uterine cancer - Fierce Biotech

Promega wins FDA approval as companion diagnostic for Keytruda-Lenvima combo in uterine cancer Fierce Biotech

Published: Nov. 13, 2025, 9 a.m.
FDA Approves Promega OncoMate® MSI Dx as Companion Diagnostic for KEYTRUDA® and LENVIMA® in Endometrial Cancer - Voice Of HealthCare

FDA Approves Promega OncoMate® MSI Dx as Companion Diagnostic for KEYTRUDA® and LENVIMA® in Endometrial Cancer Voice Of HealthCare

Published: Nov. 13, 2025, 6:17 a.m.
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - 뉴스와이어

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma 뉴스와이어

Published: Nov. 13, 2025, 5:50 a.m.
Long noncoding RNAs and microRNAs in Endometriosis.

Endometriosis represents a prevalent gynaecological disorder, impacting around 10% of the female population and affecting as many as 50% of women who are facing challenges with infertility. The pathogenesis of …

Published: Nov. 13, 2025, midnight
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer - CancerNetwork

FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer CancerNetwork

Published: Nov. 12, 2025, 7:12 p.m.
Gynaecological Devices Market Set to Reach USD 21.11 Billion By 2033, Due to Advances in Surgical and Diagnostic Technologies – SNS Insider - Business Upturn

Gynaecological Devices Market Set to Reach USD 21.11 Billion By 2033, Due to Advances in Surgical and Diagnostic Technologies – SNS Insider Business Upturn

Published: Nov. 12, 2025, 1 p.m.
Proteomics $2.2M R&D rebate to fuel diagnostics test rollout - The Sydney Morning Herald

Proteomics $2.2M R&D rebate to fuel diagnostics test rollout The Sydney Morning Herald

Published: Nov. 12, 2025, 5:39 a.m.
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - BioSpace

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma BioSpace

Published: Nov. 12, 2025, 4:01 a.m.
Post-tubectomy scar endometriosis: an uncommon sequela of a common procedure.

Scar endometriosis is a rare form of extra-pelvic endometriosis that occurs at the site of surgical scars, most frequently after obstetric or gynaecologic procedures. This condition is often confused with …

Published: Nov. 12, 2025, midnight
The Diagnostic Accuracy of Magnetic Resonance Imaging Versus Transvaginal Ultrasound in Deep Infiltrating Endometriosis and Their Impact on Surgical Decision-Making: A Systematic Review.

Objectives: This study aimed to systematically compare the diagnostic accuracy of magnetic resonance imaging (MRI) and transvaginal ultrasound (TVUS) for deep infiltrating endometriosis (DIE) and to evaluate their impact on …

Published: Nov. 12, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!